International Clinical Trial: A Phase III Randomized Controlled Study Comparing Systemic Chemotherapy Combined with Sintilimab with or Without Albumin-Bound Paclitaxel for Intraperitoneal Perfusion in the Treatment of Previously Untreated HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma with Peritoneal Metastasis

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127138) titled 'A Phase III Randomized Controlled Study Comparing Systemic Chemotherapy Combined with Sintilimab with or Without Albumin-Bound Paclitaxel for Intraperitoneal Perfusion in the Treatment of Previously Untreated HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma with Peritoneal Metastasis' on June 25.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Sun Yat-sen University Cancer Center

Condition: To treat newly diagnosed HER2-negative gastric/esophagogastric junction adenocarcinoma with peritoneal metastasis

Intervention: Experimental group (group A):SOX+ sintilimab group (g...